Skip to content

Objective to explore the dose effect relationship of continuous sedation of rimazolom and its effect on ischemia-reperfusion after tourniquet in orthopedic surgery

Objective to explore the dose effect relationship of continuous sedation of rimazolom and its effect on ischemia-reperfusion after tourniquet in orthopedic surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035274
Enrollment
Unknown
Registered
2020-08-06
Start date
2020-08-10
Completion date
Unknown
Last updated
2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical sedation and ischemia reperfusion

Interventions

Experimental group:Different doses of remidazolam were pumped
Experimental group E:Effective dose of remidazolam was pumped
Control group F :Midazolam pump injection
Group B:Pumping normal saline
Group M:Midazolam was pumped

Sponsors

Shaoyang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients with ASA I - II grade; 2. Patients without contraindications of intraspinal anesthesia; 3. Patients aged 40-60 years; 4. Patients with body mass index (BMI) of 18.5-24 kg / m2; 5. Patients with bmr-11% - 11%.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of cardiovascular system, central nervous system and mental illness; 2. Patients with history of sleep apnea hypopnea syndrome and respiratory failure; 3. Patients with a history of endocrine diseases such as hyperthyroidism, hypothyroidism and chronic adrenocortical hypofunction (Addison's disease); 4. Patients with history of dependence or allergy to analgesics and sedatives; 5. Patients with liver and kidney dysfunction; 6. Patients with communication barriers; 7. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Bispectral index;modified observer's assessment of alert /sedation;malondialdehyde;Superoxide dismutase;Interleukin-6;Tumor necrosis factor - a;miR-92a;vascular endothelial growth factor;

Secondary

MeasureTime frame
Forgetting test;

Countries

China

Contacts

Public ContactBinghua He

Shaoyang Central Hospital

272138377@qq.com+86 13574909298

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026